---
figid: PMC8490190__jmd-21035f2
figtitle: 'Emerging Nondopaminergic Medications for Parkinson’s Disease: Focusing
  on A2A Receptor Antagonists and GLP1 Receptor Agonists'
organisms:
- Homo sapiens
- Mus musculus
- Rattus norvegicus
- Macaca mulatta
- Bikinia letestui
- Heloderma suspectum
organisms_ner:
- Mus musculus
- Rattus norvegicus
- Macaca mulatta
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC8490190
filename: jmd-21035f2.jpg
figlink: /pmc/articles/PMC8490190/figure/f2-jmd-21035/
number: F2
caption: 'Possible mechanisms of GLP1 agonists on PD. Exenatide activates the GLP1
  receptor and further promotes PI3K/AKT pathway signaling. PI3K/AKT activates the
  mTOR pathway but inhibits the FoxO1/O3, GSK-3β, and NF-κB pathways. Activation of
  the PI3K/AKT pathway enhances neurogenesis, LTP, and mitochondrial function with
  a decrease in apoptosis and microglial activation. Moreover, GLP1R agonists activate
  adenylate cyclase and facilitate cAMP biosynthesis with CREB. CREB further promotes
  Bcl-2 and Bcl-XL transcription to prevent apoptosis. cAMP also activates the PKA/MAPK
  pathway and increases synaptic plasticity. PKA-dependent phosphorylation of L-type
  calcium channels potentiates calcium influx and increases neuronal activities. Bcl-2:
  B-cell lymphoma 2, Bcl-XL: B-cell lymphoma-extra large, cAMP: cyclic adenosine monophosphate,
  CREB: cAMP-response element-binding protein, FoxO1/O3: forkhead box transcription
  factor 1/3, GLP1R: glucagon-like peptide-1 receptor, GSK-3β: glycogen synthase kinase-3β,
  LTP: long-term potentiation, MAPK: mitogen-activated protein kinase, mTOR: mammalian
  target of rapamycin, NF-κB: nuclear factor kappa B, PD: Parkinson’s disease, PI3K:
  phosphoinositide 3-kinase, PKA: protein kinase A.'
papertitle: 'Emerging Nondopaminergic Medications for Parkinson’s Disease: Focusing
  on A2A Receptor Antagonists and GLP1 Receptor Agonists.'
reftext: Pei Shang, et al. J Mov Disord. 2021 Sep;14(3):193-203.
year: '2021'
doi: 10.14802/jmd.21035
journal_title: Journal of Movement Disorders
journal_nlm_ta: J Mov Disord
publisher_name: The Korean Movement Disorder Society
keywords: A2A receptor antagonist | GLP1 receptor agonist | Parkinson’s disease
automl_pathway: 0.9443933
figid_alias: PMC8490190__F2
figtype: Figure
redirect_from: /figures/PMC8490190__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8490190__jmd-21035f2.html
  '@type': Dataset
  description: 'Possible mechanisms of GLP1 agonists on PD. Exenatide activates the
    GLP1 receptor and further promotes PI3K/AKT pathway signaling. PI3K/AKT activates
    the mTOR pathway but inhibits the FoxO1/O3, GSK-3β, and NF-κB pathways. Activation
    of the PI3K/AKT pathway enhances neurogenesis, LTP, and mitochondrial function
    with a decrease in apoptosis and microglial activation. Moreover, GLP1R agonists
    activate adenylate cyclase and facilitate cAMP biosynthesis with CREB. CREB further
    promotes Bcl-2 and Bcl-XL transcription to prevent apoptosis. cAMP also activates
    the PKA/MAPK pathway and increases synaptic plasticity. PKA-dependent phosphorylation
    of L-type calcium channels potentiates calcium influx and increases neuronal activities.
    Bcl-2: B-cell lymphoma 2, Bcl-XL: B-cell lymphoma-extra large, cAMP: cyclic adenosine
    monophosphate, CREB: cAMP-response element-binding protein, FoxO1/O3: forkhead
    box transcription factor 1/3, GLP1R: glucagon-like peptide-1 receptor, GSK-3β:
    glycogen synthase kinase-3β, LTP: long-term potentiation, MAPK: mitogen-activated
    protein kinase, mTOR: mammalian target of rapamycin, NF-κB: nuclear factor kappa
    B, PD: Parkinson’s disease, PI3K: phosphoinositide 3-kinase, PKA: protein kinase
    A.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Gcg
  - Ehmt1
  - Zglp1
  - Foxo1
  - Gsk3b
  - Pik3r1
  - Akt1
  - Nfkb1
  - act
  - Fhl5
  - Acot7
  - Mtor
  - Ltp
  - Creb1
  - Bcl2
  - Bcl2l1
  - Bc1
  - Bc1-ps1
  - Igkv1-136
  - Mapt
  - Pik3cg
  - FOXO1
  - GSK3B
  - MTOR
  - PRKACA
  - BCL2
  - GCG
  - GLP1R
  - EHMT1
  - ZGLP1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - NFKB1
  - SERPINA3
  - ACTG1
  - ACTG2
  - FHL5
  - ACOT7
  - ACTBL2
  - POTEKP
  - POTEM
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACB
  - PRKACG
  - CHMP2A
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - GlyP
  - foxo
  - sgg
  - gskt
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - Dif
  - dl
  - Rel
  - Act5C
  - .na.character
  - Act42A
  - Actbeta
  - Tor
  - Apoltp
  - CrebB
  - CrebA
  - Pka-C1
  - Pka-R2
  - Pka-C3
  - Pka-R1
  - Pka-C2
  - Debcl
  - bc2
  - BC1
  - MKP-4
  - p38b
  - rl
---
